NEW YORK (GenomeWeb News) – Boehringer Ingelheim researchers will use IDBS’ predictive modeling technology in its drug discovery research programs, IDBS said today.
Pharmaceutical researchers at Boehringer Ingelheim’s Biberach an der Riss facility will use IDBS’ PredictionBase “to increase efficiency of the candidate identification process,” IDBS founder and CEO Neil Kipling said in a statement.
Guildford, UK-based IDBS said the scientists will use PredictionBase to build, deploy, and distribute predictive ADME quantitative structure-activity relationship models using existing data.
Financial terms of the agreement were not released.
In addition to its UK headquarters, IDBS has offices in California, New Jersey, and Massachusetts.